WO2018230936A1 - NOUVEAU COMPOSÉ PRÉSENTANT UNE DOUBLE ACTIVITÉ PPARα/γ ET COMPOSITION POUR PRÉVENIR OU TRAITER UNE MALADIE MÉTABOLIQUE CONTENANT LEDIT COMPOSÉ EN TANT QUE PRINCIPE ACTIF - Google Patents
NOUVEAU COMPOSÉ PRÉSENTANT UNE DOUBLE ACTIVITÉ PPARα/γ ET COMPOSITION POUR PRÉVENIR OU TRAITER UNE MALADIE MÉTABOLIQUE CONTENANT LEDIT COMPOSÉ EN TANT QUE PRINCIPE ACTIF Download PDFInfo
- Publication number
- WO2018230936A1 WO2018230936A1 PCT/KR2018/006649 KR2018006649W WO2018230936A1 WO 2018230936 A1 WO2018230936 A1 WO 2018230936A1 KR 2018006649 W KR2018006649 W KR 2018006649W WO 2018230936 A1 WO2018230936 A1 WO 2018230936A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pparα
- compound
- formula
- preventing
- active ingredient
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 63
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 22
- 239000004480 active ingredient Substances 0.000 title claims abstract description 15
- 102000023984 PPAR alpha Human genes 0.000 title claims description 48
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 title claims description 48
- 208000016097 disease of metabolism Diseases 0.000 title claims description 7
- 239000000203 mixture Substances 0.000 title abstract description 14
- 230000009977 dual effect Effects 0.000 title description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 23
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 11
- 229940125542 dual agonist Drugs 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 235000013402 health food Nutrition 0.000 claims description 9
- RTYVORPNMMHKDM-UHFFFAOYSA-N C(C=CC1=CC=CC=C1)(=O)C=1C(OC2=C(C(=CC(=C2C=1C1=CC=CC=C1)O)O)C)=O Chemical compound C(C=CC1=CC=CC=C1)(=O)C=1C(OC2=C(C(=CC(=C2C=1C1=CC=CC=C1)O)O)C)=O RTYVORPNMMHKDM-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract description 63
- 230000000694 effects Effects 0.000 abstract description 32
- 229960004586 rosiglitazone Drugs 0.000 abstract description 28
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 17
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 15
- 208000004930 Fatty Liver Diseases 0.000 abstract description 14
- 208000010706 fatty liver disease Diseases 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 12
- 230000004580 weight loss Effects 0.000 abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 231100000304 hepatotoxicity Toxicity 0.000 abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 abstract description 5
- 206010019851 Hepatotoxicity Diseases 0.000 abstract description 4
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 abstract description 4
- 230000007686 hepatotoxicity Effects 0.000 abstract description 4
- 230000006866 deterioration Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 34
- 108010016731 PPAR gamma Proteins 0.000 description 29
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 24
- 239000008103 glucose Substances 0.000 description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000003981 vehicle Substances 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- 210000001789 adipocyte Anatomy 0.000 description 17
- 238000007254 oxidation reaction Methods 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000010410 layer Substances 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 9
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 206010022489 Insulin Resistance Diseases 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 7
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 6
- 102000049320 CD36 Human genes 0.000 description 6
- 108010045374 CD36 Antigens Proteins 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical group ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 5
- 108010081805 Malonyl-CoA decarboxylase Proteins 0.000 description 5
- 102100029461 Malonyl-CoA decarboxylase, mitochondrial Human genes 0.000 description 5
- 241000242739 Renilla Species 0.000 description 5
- 108091006299 SLC2A2 Proteins 0.000 description 5
- 108091006300 SLC2A4 Proteins 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010044210 PPAR-beta Proteins 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 102100023537 Solute carrier family 2, facilitated glucose transporter member 2 Human genes 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004262 dental pulp cavity Anatomy 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 3
- MZKLJZUYIWDMTM-UHFFFAOYSA-N 5,7-dihydroxy-6-methyl-4-phenylchromen-2-one Chemical compound OC1=C2C(=CC(OC2=CC(=C1C)O)=O)C1=CC=CC=C1 MZKLJZUYIWDMTM-UHFFFAOYSA-N 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
- 101710083182 Fatty acid-binding protein 1 Proteins 0.000 description 3
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 description 3
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 description 3
- 101710189565 Fatty acid-binding protein, liver-type Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 3
- 102000043296 Lipoprotein lipases Human genes 0.000 description 3
- -1 MD001 Compound Chemical class 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 3
- 229960005095 pioglitazone Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- BPHYZRNTQNPLFI-UHFFFAOYSA-N 2,4,6-trihydroxytoluene Chemical compound CC1=C(O)C=C(O)C=C1O BPHYZRNTQNPLFI-UHFFFAOYSA-N 0.000 description 2
- FKNGTJUNAZYRPV-UHFFFAOYSA-N 5,7-dihydroxy-8-methyl-4-phenylchromen-2-one Chemical compound C=1C(=O)OC=2C(C)=C(O)C=C(O)C=2C=1C1=CC=CC=C1 FKNGTJUNAZYRPV-UHFFFAOYSA-N 0.000 description 2
- KPFYEAWSYOGWJG-UHFFFAOYSA-N 5,7-dimethoxy-6-methyl-4-phenylchromen-2-one Chemical compound COC1=C2C(=CC(OC2=CC(=C1C)OC)=O)C1=CC=CC=C1 KPFYEAWSYOGWJG-UHFFFAOYSA-N 0.000 description 2
- WZYQYFNRLFKQME-UHFFFAOYSA-N 5,7-dimethoxy-8-methyl-4-phenylchromen-2-one Chemical compound COC1=C2C(=CC(OC2=C(C(=C1)OC)C)=O)C1=CC=CC=C1 WZYQYFNRLFKQME-UHFFFAOYSA-N 0.000 description 2
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- XKLQHYYUJOEQNT-UHFFFAOYSA-N C(C=CC1=CC=CC=C1)(=O)C=1C(OC2=CC(=C(C(=C2C=1C1=CC=CC=C1)OC)C)OC)=O Chemical compound C(C=CC1=CC=CC=C1)(=O)C=1C(OC2=CC(=C(C(=C2C=1C1=CC=CC=C1)OC)C)OC)=O XKLQHYYUJOEQNT-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- GKKZMYDNDDMXSE-UHFFFAOYSA-N Ethyl 3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CC=C1 GKKZMYDNDDMXSE-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 229940126033 PPAR agonist Drugs 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UNHKDNPFEKYKRG-OUKQBFOZSA-N 5,7-dihydroxy-6-methyl-4-phenyl-8-[(e)-3-phenylprop-2-enoyl]chromen-2-one Chemical compound C=12OC(=O)C=C(C=3C=CC=CC=3)C2=C(O)C(C)=C(O)C=1C(=O)\C=C\C1=CC=CC=C1 UNHKDNPFEKYKRG-OUKQBFOZSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- KAETVIGAKYXUHW-UHFFFAOYSA-N C(C=CC1=CC=CC=C1)(=O)C=1C(OC2=C(C(=CC(=C2C=1C1=CC=CC=C1)OC)OC)C)=O Chemical compound C(C=CC1=CC=CC=C1)(=O)C=1C(OC2=C(C(=CC(=C2C=1C1=CC=CC=C1)OC)OC)C)=O KAETVIGAKYXUHW-UHFFFAOYSA-N 0.000 description 1
- RJASNJDZNLSUMO-UHFFFAOYSA-N C(C=CC1=CC=CC=C1)(=O)C=1C(OC2=CC(=C(C(=C2C=1C1=CC=CC=C1)O)C)O)=O Chemical compound C(C=CC1=CC=CC=C1)(=O)C=1C(OC2=CC(=C(C(=C2C=1C1=CC=CC=C1)O)C)O)=O RJASNJDZNLSUMO-UHFFFAOYSA-N 0.000 description 1
- 0 C*c1c(C(c2ccccc2)=C(C(C=Cc2ccccc2)=O)C(O2)=O)c2c(C)c(OC)c1 Chemical compound C*c1c(C(c2ccccc2)=C(C(C=Cc2ccccc2)=O)C(O2)=O)c2c(C)c(OC)c1 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000016831 Congenital muscular dystrophy with hyperlaxity Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 102000057621 Glycerol kinases Human genes 0.000 description 1
- 108700016170 Glycerol kinases Proteins 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 1
- 101000906283 Homo sapiens Solute carrier family 2, facilitated glucose transporter member 1 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101100290485 Medicago sativa CMDH gene Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 1
- 102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- UNHKDNPFEKYKRG-UHFFFAOYSA-N interruptin B Natural products C=12OC(=O)C=C(C=3C=CC=CC=3)C2=C(O)C(C)=C(O)C=1C(=O)C=CC1=CC=CC=C1 UNHKDNPFEKYKRG-UHFFFAOYSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
Definitions
- the present invention relates to a composition for treating metabolic diseases containing a novel compound having a PPAR ⁇ / ⁇ dual action activity or a pharmaceutically acceptable salt thereof as an active ingredient.
- Obesity is a disease that causes a variety of diseases, 80% of diabetics, 21% of heart disease patients are caused by obesity, nonalcoholic fatty liver disease is also reported as the main cause of obesity.
- Non-alcoholic fatty liver disease refers to a disease in which triglycerides accumulate in the liver regardless of drinking, and are known as steatosis and non-alcoholic steatohepatitis (NASH). ) Is included. Simple fatty liver is considered to be a benign disease with a good prognosis, but NASH with inflammation or fibrosis along with fatty liver has been reported as a proliferative disease that causes cirrhosis or liver cancer as a progressive liver disease.
- Obesity and insulin resistance are risk factors for representative non-alcoholic fatty liver disease. 69-100% of non-alcoholic fatty liver patients are obese, 20-40% of obese patients have non-alcoholic fatty liver, and the prevalence of liver disease among male obese patients is higher than that of female obese. In society, 3-30% of normal weight adults as well as obese patients are reported to have non-alcoholic fatty liver lesions.
- NAFDL nonalcoholic fatty liver disease
- the first is to improve the fatty liver by correcting risk factors such as obesity treatment (Zenical), insulin resistance treatment (Metformin, pioglitazone, rosiglitazone), hyperlipidemia treatment (clofibrate, gemfibrozil, bezafibrate, atorvastatin, simvastatin) Drugs that treat and improve it belong here.
- metformin increases the oxidation of fatty acids, decreases fat-forming enzymes, improves insulinosis and insulin resistance.
- Chiazolidinedione, rosiglitazone, and pioglitazone activate PPAR ⁇ , a nuclear hormone receptor. Promotes absorption.
- the second type of treatment is a drug that repairs hepatocellular damage independent of risk factor correction for non-alcoholic fatty liver.
- Hepatoprotective agents ursodioxycholic acid and taurine
- antioxidants vitamins E and C
- nutrition Supplements lecithin, betaine, N-acetylcysteine, etc. belong to this, but to date, there is no ideal drug that is effective in treatment without side effects.
- the present invention has been confirmed that the problem that the PPAR agonist that has been used as a conventional diabetes treatment for worsening non-alcoholic fatty liver, solve the side effects of the PPAR agonist to exhibit a safe and excellent non-alcoholic fatty liver treatment effect to the human body
- One compound and a composition for treating metabolic diseases containing the same as an active ingredient are provided.
- the present invention provides a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof.
- R 1 to R 4 may be the same or different, respectively, hydrogen; C1 to C4 alkyl; Any one selected from the group consisting of C1 to C4 alkoxy.
- the present invention provides a pharmaceutical composition for preventing or treating metabolic diseases, which comprises the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention provides a health food for preventing or improving metabolic diseases containing the compound represented by the formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
- the compound of the present invention solves the side effects of the PPAR ⁇ agonist and is excellent in treating non-alcoholic fatty liver and hyperlipidemia.
- the composition containing the novel compound as an active ingredient can be used as a non-alcoholic fatty liver and hyperlipidemia treatment that can replace the conventional treatment.
- Figure 2 is a result of identifying the target genes induced expression by PPAR ⁇ and PPAR ⁇ activated in MD001
- Figure 2A and 2B is a human HA-PPAR ⁇ (A) and HA-PPAR ⁇ (B) expression vector, reporter in HEK293 cells Temporary co-transfection with plasmid (PPRE-pk-Luc) or control reporter plasmid (pk-Luc) and Renilla vector for 24 hours, followed by MD001 (10 ⁇ M), rosiglitazone (rosi (10 ⁇ M) or WY14643 (WY; 10 ⁇ M) Was treated with cells for 24 hours, and luciferase activity was confirmed.
- FIG. 2C shows the relative expression level of qp-PCR after synthesis of cDNA by treating MD001 (10 ⁇ M) with HepG2 cells for 24 hours, and separating total RNAs.
- Figure 2D is HepG2 cells transfected with control si-RNA, PPAR ⁇ si-RNA (D) or PPAR ⁇ si-RNA (E) for 48 hours and WY14643 (10 ⁇ M), Treatment with rosiglitazone (10 ⁇ M) or MD001 (10 ⁇ M) for 24 hours followed by cell collection RNA was isolated and qRT-PCR confirmed the relative expression level of the target gene (#, vs. control si-RNA; ⁇ , vs. control si-RNA / vehicle; ⁇ , vs.
- Figure 3 shows that MD001 induces GLUT expression to promote glucose consumption.
- HepG2 A
- differentiated 3T3-L1 adipocytes B
- differentiated C2C12 root canal cells C
- MD001 10 , 50 ⁇ M
- rosi rosiglitazone
- Figure 4 is a result of confirming the fatty acid oxidation promoting effect by MD001 in vitro
- Figures 4A, 4B and 4C are HepG2 (A), differentiated 3T3-L1 adipocytes (B) and differentiated C2C12 myotubes (C) Treatment of vehicle or MD001 (10 ⁇ M) for 24 hours, and the total RNA was isolated to synthesize cDNA and qRT-PCR to determine the relative gene expression
- Figure 4D is HepG2 (D), differentiated 3T3-L1 fat Treatment of cells (E) and differentiated C2C12 root canal cells (F) with vehicle, MD001 (10 ⁇ M) or WY14643 (WY; 10 ⁇ M) for 24 hours, and confirmed the fatty acid oxidation rate, and whether the fatty acid oxidation rate is improved by MD001
- HepG2 (G), differentiated 3T3-L1 (H), and differentiated C2C12 myotubes (I) were transfected with control or PP
- WY14643 (WY; 10 ⁇ M) as a positive control for 24 hours
- FIG. 5 is a result confirming the weight loss caused by MD001 in db / db mice
- FIG. 6 is a result of confirming the effect of improving the fatty liver by MD001 in db / db mice
- Figure 6A is ingested vehicle, rosiglitazone (rosi; 20mg / kg) or MD001 (5 or 20mg / kg) for 4 weeks in db / db mice
- FIG. 6B is liver triglycerol (TG).
- FIG. 6C is cholesterol
- FIG. 6D is a result of quantitative analysis of free fatty acid levels.
- FIG. 6E is performed by qRT-PCR. This is the result of confirming the relative expression level of each gene in db / db mice (*, **, vs. vehicle.The data represent the mean ⁇ SD * P ⁇ 0.01, ** P ⁇ 0.05).
- FIG. 7 is a result of confirming the effect of reducing the size and macrophage infiltration of fat cells by MD001
- Figure 7A is a result of performing the H & E staining by collecting the adipose tissue of db / db mice
- Figure 7B is a high power HPF ( The average number of fat cells per field) is calculated
- FIG. 7C is a result of confirming relative gene expression by qRT-PCR.
- FIGS. 7D and 7E are CLS (Crown-like structures) of fat cells in white adipose tissue. (*, **, vs. vehicle; ⁇ , vs. rosi.The data represent the mean ⁇ SD * P ⁇ 0.05, ** P ⁇ 0.01, and ⁇ P ⁇ 0.01).
- the present invention can provide a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof.
- R 1 to R 4 may be the same or different, respectively, hydrogen; C1 to C4 alkyl; Alkoxy of C1 to C4; It may be any one selected from the group consisting of halogen.
- the compound represented by Formula 1 or a pharmaceutically useful salt thereof may be 3-cinnamoyl-5,7-dihydroxy-8-methyl-4-phenyl-2H-chromen-2-one.
- the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof may be a PPAR ⁇ / ⁇ dual agonist.
- HEK293 cells are transient for 24 hours with human HA-PPAR ⁇ and HA-PPAR ⁇ expression vectors, reporter plasmids (PPRE-pk-Luc) or control reporter plasmids (pk-Luc) and Renilla vectors.
- reporter plasmids PPRE-pk-Luc
- pk-Luc control reporter plasmids
- Renilla vectors As a result of treatment of the compounds with co-transfected HEK293 cells at 20 ⁇ M for 24 hours and luciferase activity, compound 8a (MD001) simultaneously confirmed the transcriptional activity of PPAR ⁇ and PPAR ⁇ as shown in FIG. 1.
- the compound represented by Formula 1 may be used as a PPAR ⁇ / ⁇ dual agonist.
- the present invention can provide a pharmaceutical composition for preventing or treating metabolic diseases containing the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the compound represented by Formula 1 or a pharmaceutically useful salt thereof may be 3-cinnamoyl-5,7-dihydroxy-8-methyl-4-phenyl-2H-chromen-2-one, and Formula 1
- the compound represented by or a pharmaceutically acceptable salt thereof may be a PPAR ⁇ / ⁇ dual agonist.
- the metabolic disease may be selected from the group consisting of nonalcoholic fatty liver and hyperlipidemia.
- Peros Peroxisome proliferator-activated receptors
- PPAR ⁇ Peroxisome proliferator-activated receptors
- PPAR ⁇ / ⁇ and PPAR ⁇ one of the nuclear hormone receptor family
- PPAR ⁇ or PPAR ⁇ / ⁇ Activation of PPAR ⁇ or PPAR ⁇ / ⁇ is known to induce the expression of genes that regulate fatty acid oxidation to promote lipid consumption by promoting lipid consumption, whereas PPAR ⁇ induces the expression of lipid carrier genes including adipocyte fatty acid binding protein and CD36.
- PPAR ⁇ agonists cannot be used to treat fatty liver or hyperlipidemia because they promote lipid production in adipocytes.
- rosiglitazone a conventional PPAR ⁇ agonist, exacerbated hepatic steatosis, while MD001 was treated, MD001 dose-dependent liver fat.
- the compound MD001 is found to improve fatty liver, and thus, the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof may be used as a metabolic disease treatment agent.
- the pharmaceutical composition containing the compound represented by the formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient is an injection, granules, powders, tablets, pills, capsules, Any formulation selected from the group consisting of suppositories, gels, suspensions, emulsions, drops or solutions may be used.
- the pharmaceutical composition containing the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient is a suitable carrier, excipient, disintegrant, sweetener commonly used in the preparation of the pharmaceutical composition. It may further comprise one or more additives selected from the group consisting of coatings, expanding agents, lubricants, lubricants, flavoring agents, antioxidants, buffers, bacteriostatic agents, diluents, dispersants, surfactants, binders and lubricants.
- the carriers, excipients and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil can be used, and solid preparations for oral administration include tablets, pills, powders, granules, capsules.
- solid preparations may be prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin and the like in the composition.
- excipients such as starch, calcium carbonate, sucrose or lactose, gelatin and the like
- lubricants such as magnesium styrate and talc may also be used.
- Oral liquid preparations include suspensions, solvents, emulsions, syrups, and the like, and may include various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and the like.
- non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
- Witsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like may be used as the base material of the suppository.
- the pharmaceutical composition is intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, intrasternal, transdermal, nasal, inhaled, topical, rectal, oral, intraocular or intradermal Via the route can be administered to the subject in a conventional manner.
- the preferred dosage of the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof may vary depending on the condition and weight of the subject, the type and severity of the disease, the form of the drug, the route and duration of administration, and may be appropriately selected by those skilled in the art. Can be. According to one embodiment of the present invention, but not limited thereto, the daily dosage may be 0.01 to 200 mg / kg, specifically 0.1 to 200 mg / kg, more specifically 0.1 to 100 mg / kg. Administration may be administered once a day or divided into several times, thereby not limiting the scope of the invention.
- the 'subject' may be a mammal including a human, but is not limited thereto.
- the present invention may be provided as a health food for preventing or improving metabolic diseases containing a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
- the compound represented by Formula 1 or a pharmaceutically useful salt thereof may be 3-cinnamoyl-5,7-dihydroxy-8-methyl-4-phenyl-2H-chromen-2-one, and Formula 1
- the compound represented by or a pharmaceutically acceptable salt thereof may be a PPAR ⁇ / ⁇ dual agonist.
- the metabolic disease may be selected from the group consisting of nonalcoholic fatty liver and hyperlipidemia.
- the health food is used with other foods or food additives in addition to the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, and may be appropriately used according to a conventional method.
- the mixed amount of the active ingredient may be appropriately determined depending on the purpose of use thereof, for example, prophylactic, health or therapeutic treatment.
- the effective dose of the compound contained in the health food may be used in accordance with the effective dose of the therapeutic agent, but may be less than the above range in the case of long-term intake for health and hygiene purposes or health control purposes It is evident that the component can be used in an amount above the range because there is no problem in terms of safety.
- Methyl phloroglucinol (2.0 g, 14.3 mmol), ethyl benzoyl acetate (g, 28.6 mmol, 2.0 eq.), Trifluoroacetic acid (2 mL) and AcOH (40 mL ) was placed in a round bottom flask and heated for 12 hours to reflux the mixture.
- Methyl phloroglucinol (4.0 g, 24.6 mmol), ethyl benzoyl acetate (9.90 mL, 57.2 mmol, 2.0 eq.), Trifluoroacetic acid (4 mL) and AcOH (100 mL) were placed in a round bottom flask for 12 hours. After refluxing with heat, the reaction mixture was concentrated under reduced pressure.
- Acetone was removed under reduced pressure, and the organic layer was separated by dissolving the residue in water (50 mL) / EtOAc (50 mL).
- the aqueous layer was extracted with EtOAc (50 mL ⁇ 2) and the organic layer was washed twice with water (10 mL ⁇ 2), dried over MgSO 4 , concentrated under reduced pressure and adsorbed onto silica gel.
- the first reaction compound exhibited high insolubility in a general purification system and was obtained in significantly smaller amounts, so instead of purifying the mixture, the crude mixture was concentrated under reduced pressure and volatiles were removed under high vacuum conditions.
- the washed organic layer was dried over MgSO 4 and concentrated under reduced pressure.
- the washed organic layer was dried over MgSO 4 and concentrated under reduced pressure.
- Acetone was removed under reduced pressure, and the residue was dissolved in water (50 mL) / EtOAc (50 mL) and the organic layer was separated.
- the cells were maintained at 37 ° C. in a humidification chamber containing 5% CO 2 .
- HepG2 cells were cultured in minimum Eagle's medium (MEM) medium containing 10% FBS and 1% penicillin and streptomycin.
- MEM minimum Eagle's medium
- HEK293, C2C12 and 3T3-L1 cells were maintained in DMEM (Dulbecco's modified Eagle's medium) medium containing 10% FBS and 1% penicillin and streptomycin.
- DMEM Dulbecco's modified Eagle's medium
- Plasmid DNA constructs were transfected into cells with polyethyleneimine (EI, Polysciences, Inc., PA, USA) according to the manufacturer's instructions.
- HA-PPAR ⁇ , HA-PPAR ⁇ , PPRE reporter plasmid (PPRE-pk-Luc) or control reporter plasmid (pk-Luc) and Renilla vector were co-coated for 24 hours.
- cells were treated with Int B, rosiglitazone (Sigma-Aldrich, USA) or WY14643 (Sigma-Aldrich, USA) at various concentrations for 24 hours.
- Luciferase activity was confirmed by the Dual-Luciferase Reporter Assay System (Promega, WI, USA), and quantitated according to the manufacturer's protocol using GloMax® (Promega, WI, USA).
- PPAR ⁇ and PPAR ⁇ targeting si-RNA were transfected into HepG2, 3T3-L1 or C2C12 cells using Lipofectamine 2000 (Invitrogen, USA) for 48 hours.
- GAPDH was used as an internal control, and primers of the sequences shown in Tables 1 and 2 were used.
- primer sequence species PPAR ⁇ F 5'-CGGTGACTTATCCTGTGGTCC-3 Human R, 5'-CCGCAGATTCTACATTCGATGTT-3 ' PPAR ⁇ F, 5'-TACTGTCGGTTTCAGAAATGCC-3 ' R, 5'-GTCAGCGGACTCTGGATTCAG-3 ' RXR F, 5'-GACGGAGCTTGTGTCCAAGAT-3 ' R, 5’-AGTCAGGGTTAAAGAGGACGAT-3 ’ ACOX F, 5'-ACTCGCAGCCAGCGTTATG-3 ' R, 5'-AGGGTCAGCGATGCCAAAC-3 ' CPT F, 5'-TCCAGTTGGCTTATCGTGGTG-3 ' R, 5'-TCCAGAGTCCGATTGATTTTTGC-3 ' MLYCD F, 5'-ACGTCCGGGAAATGAATGGG-3 ' R, 5'-GTAACCCGTTCTAGGTTCAGGA-3 ' FATP F, 5'-CTTCGA
- primer sequence species PPAR ⁇ F 5'-TCTTCACGATGCTGTCCTCCT-3 ' mouse R, 5'-CTATGTTTAGAAGGCCAGGC-3 ' GLUT2 F, 5'-TTCCAGTTCGGCTATGACATCG-3 ' R, 5'-CTGGTGTGACTGTAAGTGGGG-3 ' GK F, 5'-TGAACCTGAGGATTTGTCAGC-3 ' R, 5'-CCATGTGGAGTAACGGATTTCG-3 ' CD36 F, 5'-ATGGGCTGTGATCGGAACTG-3 ' R, 5'-GTCTTCCCAATAAGCATGTCTCC-3 ' LPL F, 5'-TTGCCCTAAGGACCCCTGAA-3 ' R, 5'-TTGAAGTGGCAGTTAGACACAG-3 ' GLUT4 F, 5'-ACACTGGTCCTAGCTGTATTCT-3 ' R, 5'-CCAGCCACGTTGCATTGTA-3 ' ACOX F, 5'-TGTTAAGA
- fatty acid oxidation analysis cells were cultured with 0.1 mM palmitate (9, 10- [ 3 H] palmitate, 5 ⁇ ci / ml; Perkin Elmer Life, Boston, Mass.) And a-MEM (Hyclone) containing 1% bovine serum albumin. , USA) for 24 hours.
- the medium was collected, precipitated with 10% trichloroacetic acid (Sigma-Aldrich, USA), mixed vigorously, incubated at room temperature for 20 minutes, and centrifuged at 4 ° C. and 16,000 g for 10 minutes.
- 10% trichloroacetic acid Sigma-Aldrich, USA
- the supernatant was transferred to a 1.5 ml tube, placed in a scintillation vial containing 0.5 ml water and incubated at 60 ° C. for 12 hours.
- radioactivity 3 H 2 O in water was quantified using a liquid scintillation counter (LKB, USA).
- Interruptin B and rosiglitazone were treated with the cells for 3 days, and the cells cultured in conditioned medium were collected and analyzed for glucose content using Glucose Colorimetric Assay Kit II (BioVision Inc., CA, USA).
- SPR Surface plasmon resonance
- Int B was treated at 31.25, 62.5, 125, 250, and 500 ⁇ M concentrations and KD values were determined using the Scrubber 2 program (Informer Technologies, Inc., TX, USA).
- mice were fasted for 12 hours, sterile glucose (1 g / kg, Sigma-Aldrich, USA) was taken and blood glucose levels were checked at the designated times using OneTouch Ultra (LifeScan Inc., USA).
- Serum and liver TG, FFA, and total cholesterol were measured using Hitachi clinical analyzer 7180 (HITACHI, JAPAN) and WAKO reagent (WAKO, USA).
- Serum LDL and HDL contents were measured using SEKISUI reagent (SEKISUI, JAPAN).
- ALT alanine aminotransferase
- AST aspartic aminotransferase
- Tissues such as liver, peripheral adipose tissue, skeletal muscle, spleen, kidney and heart were collected from each group of mice, fixed in 10% formalanine and embedded in paraffin.
- Tissues cut at 5 ⁇ m were stained with hematoxylin and eosin.
- the MD001 compound chemically synthesized from the above results was assumed to be bound to PPAR ⁇ , PPAR ⁇ / ⁇ , and PPAR ⁇ , and as a result, the compound MD001 binds to PPAR ⁇ and PPAR ⁇ and not to PPAR ⁇ / ⁇ .
- luciferase activity analysis was performed on HEK293 cells using PPRE.
- MD001 significantly increased the transcription level through PPAR ⁇ and PPAR ⁇ activity as shown in FIGS. 2A and 2B, whereas the levels of WY14643 and rosiglitazone were lower than MD001.
- MD001 is an ACOX (acyl-CoA oxidase), CPT (carnitine-palmitoyl transferase), which are PPAR ⁇ target genes related to ⁇ -oxidation in cells that have reduced expression using PPAR ⁇ si-RNA, And increased expression of middlechain acyl-CoA dehydrogenase (mCAD).
- ACOX acyl-CoA oxidase
- CPT carnitine-palmitoyl transferase
- mCAD middlechain acyl-CoA dehydrogenase
- GPAR glycol kinase
- CD36 fatty acid binding protein 1
- FABP1 fatty acid binding protein 1
- MD001 may be proposed to modulate metabolism through the specific activity of PPAR ⁇ and PPAR ⁇ as dual agents.
- PPAR ⁇ is recognized as a traditional molecular target for the development of antidiabetic drugs that enhance insulin sensitivity and glucose tolerance.
- MD001 increased glucose consumption dose-dependently, as shown in Figures 3A, 3B and 3C.
- quantitative RT-PCR analysis showed that MD001 significantly increased the expression of GLUT2 (HepG2) and GLUT4 (3T3-L1 and C2C12), as shown in FIGS. 3D, 3E and 3F.
- MD001 like 4A, 4B and 4C, expressed ACOX, CPT, malonyl-CoA decarboxylase (MLYCD) and fatty acid transporter (FATP) in HepG2 and ACOX and CPT expression in 3T3-L1 and C2C12 cells. Increased significantly.
- MD001 stimulates fatty acid oxidation, as shown in Figure 4D MD001 significantly increased the ⁇ -oxidation rate in HepG2 cells, even in 3T3-L1 and C2C12 root canal cells differentiated as 4E and 4F Similar results were confirmed.
- MD001 was treated once a day in normal C57BL / 6J mice and diabetic db / db mice.
- IPGTT intraperitoneal glucose tolerance test
- FIG. 5B and Supplementary Fig. 3A
- IPITT insulin tolerance test
- TZDs including rosiglitazone, pioglitazone and troglitazone, are known to have side effects such as severe weight loss in humans as well as animals, and MD001 has also been a cause of side effects such as weight loss.
- Rosiglitazone was used as a positive control to confirm the effect of hyperglycemia and lipid profile improvement in db / db mice.
- MD001 a PPAR ⁇ / ⁇ dual agonist as shown in FIGS. 5D-5E and 5K, significantly reduced blood glucose, triglycerol (TG) and free fatty acids in db / db mice.
- TG triglycerol
- MD001 did not affect the levels of plasma lipids and blood glucose compared to the control normal C57BL / 6J mice.
- rosiglitazone significantly increased alanine transferase (ALT) and aspartate aminotransferase (AST) levels in the blood of db / db mice, whereas MD001 treated db / db mice.
- ALT and AST levels in blood were greatly reduced, and no change was seen in normal C57BL / 6 mice.
- MD001 significantly decreased low density lipoprotein (LDL) levels and increased high density lipoprotein levels.
- LDL low density lipoprotein
- MD001 can be suggested to restore cholesterol metabolism in obese animals.
- rosiglitazone induced a significant increase in liver weight (40%) and fat mass (50%) in db / db mice, whereas MD001 did not induce an increase in liver weight or adipose tissue mass.
- MD001 was found to significantly reduce blood glucose and lipid content without weight loss and hepatotoxicity.
- Fatty liver is a common complication of obesity, insulin resistance and type 2 diabetes, while PPAR ⁇ activity is known to stimulate fat consumption and reduced lipogenesis to improve fatty liver, whereas activated PPAR ⁇ has an opposite effect on fatty liver.
- MD001 was identified as a PPAR ⁇ / ⁇ dual agonist, so that MD001 could relieve fatty liver in db / db mice.
- rosiglitazone as known, exacerbated hepatic steatosis, whereas when MD001 was treated, the size and number of hepatic fat droplets decreased depending on the MD001 dose.
- MD001 decreased liver TG and FFA, but did not reduce cholesterol, whereas rosiglitazone did not reduce liver TG.
- MD001 significantly increased the expression of PPAR ⁇ target genes ACOX, CPT and MLYCD and the expression of PPAR ⁇ target genes GLUT2, GK, and CD36 as shown in FIG. 6E.
- MD001 promotes ⁇ -oxidation to reduce hepatic steatosis or, in part, to reduce blood glucose levels by activating PPAR ⁇ .
- MD001 was found to not only increase the absorption of fatty acids and glucose, but also partially promote ⁇ -oxidation in adipose tissue as shown in FIG. 7C.
- Rosiglitazone was found to significantly increase the number of CLS in adipose tissue as shown in Figures 7D and 7E, while MD001 did not stimulate the inflammatory response of adipocytes.
- H & E staining of skeletal muscle showed no difference between vehicle control, rosiglitazone and MD001 treatment groups in db / db mice.
- MD001 significantly increased the expression of CPT, GLUT4, and lipoprotein lipase (LPL) in qRT-PCR analysis using skeletal muscle.
- MD001 may be suggested to increase glucose and fatty acid metabolism in skeletal muscle.
- MD001 may contribute to the improvement of hyperglycemia and hyperglycemia as a dual agonist of PPAR ⁇ / ⁇ .
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une composition pour le traitement de maladies métaboliques contenant un nouveau composé ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif. En particulier, contrairement à la rosiglitazone, agoniste de PPARy, qui a été classiquement utilisé en tant qu'agent thérapeutique contre le diabète et présente des effets secondaires tels que l'hépatotoxicité, la détérioration du foie gras et la perte de poids, il a été confirmé que le composé de la présente invention exerce d'excellents effets dans le traitement du foie gras non alcoolique et de l'hyperlipidémie. En conséquence, une composition contenant en tant que principe actif le nouveau composé peut être utilisée en tant qu'agent thérapeutique pour le foie gras non alcoolique et l'hyperlipidémie et peut remplacer des agents thérapeutiques classiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0073119 | 2017-06-12 | ||
KR1020170073119A KR101934197B1 (ko) | 2017-06-12 | 2017-06-12 | PPARα/γ 이중 작용 활성을 갖는 신규 화합물 및 이를 유효성분으로 함유하는 대사질환 예방 또는 치료용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018230936A1 true WO2018230936A1 (fr) | 2018-12-20 |
Family
ID=64660537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/006649 WO2018230936A1 (fr) | 2017-06-12 | 2018-06-12 | NOUVEAU COMPOSÉ PRÉSENTANT UNE DOUBLE ACTIVITÉ PPARα/γ ET COMPOSITION POUR PRÉVENIR OU TRAITER UNE MALADIE MÉTABOLIQUE CONTENANT LEDIT COMPOSÉ EN TANT QUE PRINCIPE ACTIF |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101934197B1 (fr) |
WO (1) | WO2018230936A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115894422A (zh) * | 2022-12-26 | 2023-04-04 | 上海中医药大学 | PPARγ激动剂及其组合和应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102269001B1 (ko) * | 2019-09-09 | 2021-06-25 | 동국대학교 산학협력단 | 신규한 부타놀리드 이량체 화합물 및 이를 유효성분으로 함유하는 아디포넥틴 분비 촉진용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4565882A (en) * | 1984-01-06 | 1986-01-21 | G. D. Searle & Co. | Substituted dihydrobenzopyran-2-carboxylates |
WO2002026729A2 (fr) * | 2000-09-27 | 2002-04-04 | Merck & Co., Inc. | Derives d'acide benzopyrancarboxylique utilises pour le traitement du diabete et des troubles lipidiques |
US20060089404A1 (en) * | 2002-07-30 | 2006-04-27 | Desai Ranjit C | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
KR20150110901A (ko) * | 2014-03-20 | 2015-10-05 | 현대약품 주식회사 | Pparg에 결합하되 증진제로 작용하지 않는 화합물 및 이를 유효성분으로 함유하는 pparg 관련 질병의 치료용 약학적 조성물 |
KR20150118158A (ko) * | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
-
2017
- 2017-06-12 KR KR1020170073119A patent/KR101934197B1/ko active IP Right Grant
-
2018
- 2018-06-12 WO PCT/KR2018/006649 patent/WO2018230936A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4565882A (en) * | 1984-01-06 | 1986-01-21 | G. D. Searle & Co. | Substituted dihydrobenzopyran-2-carboxylates |
WO2002026729A2 (fr) * | 2000-09-27 | 2002-04-04 | Merck & Co., Inc. | Derives d'acide benzopyrancarboxylique utilises pour le traitement du diabete et des troubles lipidiques |
US20060089404A1 (en) * | 2002-07-30 | 2006-04-27 | Desai Ranjit C | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
KR20150118158A (ko) * | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
KR20150110901A (ko) * | 2014-03-20 | 2015-10-05 | 현대약품 주식회사 | Pparg에 결합하되 증진제로 작용하지 않는 화합물 및 이를 유효성분으로 함유하는 pparg 관련 질병의 치료용 약학적 조성물 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115894422A (zh) * | 2022-12-26 | 2023-04-04 | 上海中医药大学 | PPARγ激动剂及其组合和应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20180135249A (ko) | 2018-12-20 |
KR101934197B1 (ko) | 2018-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017007162A1 (fr) | Composition d'acide azélaîque ayant un effet de dégradation des triglycérides du tissu adipeux | |
WO2012148247A2 (fr) | Composition pharmaceutique contenant de l'acétate d'acide oléanolïque en tant que principe actif pour la prévention ou le traitement de maladie à médiation par tlr ou il-6 | |
WO2018230936A1 (fr) | NOUVEAU COMPOSÉ PRÉSENTANT UNE DOUBLE ACTIVITÉ PPARα/γ ET COMPOSITION POUR PRÉVENIR OU TRAITER UNE MALADIE MÉTABOLIQUE CONTENANT LEDIT COMPOSÉ EN TANT QUE PRINCIPE ACTIF | |
WO2020218720A1 (fr) | Composition pour la prévention ou le traitement de troubles musculaires ou l'amélioration de la fonction musculaire, contenant un extrait de leonurus japonicus ou de la léonurine | |
WO2016080796A2 (fr) | Composition pharmaceutique contenant un composé sesquiterpénique et utilisable en vue de la prévention ou du traitement de maladies à médiation par stat3, et son utilisation | |
WO2015111832A1 (fr) | Composition de prévention ou de traitement de maladies liées à la prostate, contenant un extrait de poncirus trifoliata | |
WO2016048005A2 (fr) | Nouveau dérivé de pipéridine pentadiénoyl et son utilisation | |
WO2018128479A1 (fr) | Composition pour la prévention ou le traitement de maladies musculaires, comprenant comme principe actif de l'acide subérique ou un sel pharmaceutiquement acceptable de celui-ci | |
WO2019022482A2 (fr) | Composition pour prévenir ou traiter les maladies fibrotiques comprenant un extrait de dendropanax morbifera à titre de principe actif | |
WO2017188690A1 (fr) | Composition permettant d'inhiber la croissance des cellules souches cancéreuses mammaires, comprenant du phénylacétaldéhyde | |
WO2009148280A2 (fr) | Composé à base de diaryl-hépatonoïde convenant comme inhibiteur viral | |
WO2020055129A1 (fr) | Composition de traitement ou de prévention du cancer comprenant un dérivé de verbénone | |
WO2012033353A2 (fr) | Composés de sesterterpène et leur utilisation | |
WO2021206455A1 (fr) | Extrait de fraction de feuilles de mélisse-citronnelle et nouvelle composition pharmaceutique le comprenant | |
WO2021034111A1 (fr) | Nouveau dérivé de sesquiterpène et son utilisation | |
WO2021033995A1 (fr) | Composition comprenant un extrait d'amomum tsaoko pour prévenir, atténuer ou traiter une maladie liée à la sarcopénie | |
WO2020130696A1 (fr) | Composition comprenant un composé inhibant le cyp4a utilisé comme principe actif pour la prévention ou le traitement de maladies métaboliques | |
WO2023182567A1 (fr) | Peptide ayant une activité antidiabétique, complexe peptidique et son utilisation | |
WO2017018686A2 (fr) | Composition contenant de la manassantine a ou de la manassantine b pour la prévention ou le traitement de la stéatose hépatique non alcoolique | |
WO2023149768A1 (fr) | Composition pharmaceutique comprenant un inhibiteur de la désubiquitinase pour la prévention ou le traitement de maladies associées au stress du réticulum endoplasmique | |
WO2013111924A1 (fr) | Nouveau composé dérivé d'ishige foliacea et son utilisation | |
WO2023033517A1 (fr) | Composition de traitement ou de prévention de l'obésité ou maladie hépatique associée à l'obésité, comprenant des dérivés de verbénone | |
WO2022045668A1 (fr) | Composition pour induire un brunissement, contenant des exosomes de lait | |
WO2011122805A2 (fr) | Composition comprenant de l'ajoène destinée à prévenir ou à traiter une maladie due à la surexpression du lxr-alpha | |
WO2015126048A1 (fr) | Composition anti-inflammatoire comportant de la loratadine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18817078 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18817078 Country of ref document: EP Kind code of ref document: A1 |